ChemicalBook > CAS DataBase List > Lithium

Lithium

Product Name
Lithium
CAS No.
17341-24-1
Chemical Name
Lithium
Synonyms
LITHIUM ION;Lithiumcation;Lithium ion (1+);Lithium, ion (Li1+);LITHIUM ION STANDARD;LITHIUM ION CHROMATOGRAPHY STANDARD;LITHIUM, ION CHROMATOGRAPHY STANDARD SOLUTION
CBNumber
CB9398139
Molecular Formula
Li+
Formula Weight
6.94
MOL File
17341-24-1.mol
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Usbiological
Product number
281443
Product name
Lithium
Packaging
25g
Price
$333
Updated
2021/12/16
More
Less

Lithium Chemical Properties,Usage,Production

Definition

ChEBI: Lithium(1+) is a monovalent inorganic cation, a monoatomic monocation and an alkali metal cation.

Mechanism of action

Lithium therapy for disorders is believed to be effective because of its ability to reduce signal transduction through the phosphatidylinositol signaling pathway. In this pathway, the second messengers diacylglycerol and inositol 1,4,5-trisphosphate are produced from the enzymatic hydrolysis of phosphatidylinositol-4,5-bisphosphate (a membrane phospholipid) by the receptor-mediated activation of the membrane-bound, phosphatidylinositol-specific phospholipase C. The second messenger activity for inositol 1,4,5-trisphosphate is terminated by its hydrolysis in three steps by inositol monophosphatases to inactive inositol, thus completing the signaling pathway. To recharge the signaling pathway, inositol must be recycled back to phosphatidylinositol bisphosphate by inositol phospholipid–synthesizing enzymes in the CNS, because inositol is unable to cross the blood-brain barrier into the CNS in sufficient concentrations to maintain the signaling pathway. By uncompetitive inhibition of inositol phosphatases in the signaling pathway, the therapeutic plasma concentrations of lithium ion deplete the pool of inositol available for the resynthesis of phosphatidylinositol-4,5- bisphosphate, ultimately decreasing its cellular levels and, thereby,reducing the enzymatic formation of the second messengers. Thus, lithium ion restores the balance among aberrant signaling pathways in critical regions of the brain.
The effects of lithium ion on disorders are surprisingly specific because of the inability of inositol to cross the blood-brain barrier and replenish depleted inositol levels. Lithium ion exerts its greatest influence on this signaling pathway when the lithium ion concentration is at saturation conditions.
The clinical efficacy of lithium in the prophylaxis of recurrent affective episodes in bipolar disorder is characterized by a lag in onset and remains for weeks to months after discontinuation. Thus, the long-term therapeutic effect of lithium likely requires reprogramming of gene expression. Protein kinase C and GSK-3 signal transduction pathways are perturbed by chronic lithium at therapeutically relevant concentrations and have been implicated in modulating synaptic function in nerve terminals.

Pharmacokinetics

The absorption of lithium is rapid and complete within 6 to 8 hours. The absorption rate of slow-release capsules is slower and the total amount of lithium absorbed lower than with other dosage forms. Lithium is not protein bound. The elimination half-life for elderly patients (39 hours) is longer than that for adult patients (24 hours), which in turn is longer than that for adolescent patients (18 hours). The time to peak serum concentration for lithium carbonate is dependent on the dosage form (tablets, 1–3 hours; extended tab, 4 hours; slow release, 3 hours). Steady-state serum concentrations are reached in 4 days, with the desirable dose targeted to give a maintenance lithium ion plasma concentration range of 0.6 to 1.2 mEq/L, with a level of 0.5 mEq/L for elderly patients. The risk of bipolar recurrence was approximately threefold greater for patients with lithium dosages that gave plasma concentrations of 0.4 to 0.6 mEq/L. Adverse reactions are frequent at therapeutic doses, and adherence is a big problem. Toxic reactions are rare at serum lithium ion levels of less than 1.5 mEq/L. Mild to moderate toxic reactions may occur at levels from 1.5 to 2.5 mEq/L, and severe reactions may be seen at levels from 2.0 to 2.5 mEq/L, depending on individual response. The onset of therapeutic action for clinical improvement is 1 to 3 weeks. Renal elimination of lithium ion is 95%, with 80% actively reabsorbed in the proximal tubule. The rate of lithium ion urinary excretion decreases with age. Fecal elimination is less than 1%.

Clinical Use

For many years, lithium has been the treatment of choice for bipolar disorder, because it can be effective in smoothing out the mood swings common to this condition. Its use must be carefully monitored, however, because the range between an effective and a toxic dose is small.Lithium carbonate (Eskalith) is the most commonly used salt of lithium to treat manic depression. Lithium carbonate dosage forms are labeled in mg and mEq/dosage unit, and lithium citrate (Lithobid) is labeled as mg equivalent to lithium carbonate and mEq/dosage unit. Lithium is effectively used to control and prevent manic episodes in 70 to 80% of those with bipolar disorder as well as to treat other forms of depression. Those who respond to lithium for depression often are those who have not responded to TCAs after several weeks of treatment. When giving lithium in addition to their antidepressants, some of these people have shown significant improvement.

Side effects

Common side effects of lithium include nausea, loss of appetite, and mild diarrhea, which usually taper off within first few weeks. Dizziness and hand tremors also have been reported. Increased production of urine and excessive thirst are two common side effects that usually are not serious problems, but patients with kidney disease should not be given lithium. Taking the day's dosage of lithium at bedtime also seems to help with the problem of increased urination. Other side effects of lithium include weight gain, hypothyroidism, increased white blood cell count, skin rashes, and birth defects.
While on lithium, a patient's blood level must be closely monitored. If the blood level of lithium ion is too low, the patient's symptoms will not be relieved. If the blood level of lithium ion is too high, there is a danger of a toxic reaction.

Drug interactions

Lithium pharmacokinetics may be influenced by a number of factors, including age. Elderly patients require lower doses of lithium to achieve serum concentrations similar to those observed in younger adults as a result of reduced volume of distribution and reduced renal clearance. Lithium ion clearance decreases as the glomerular filtration rate decreases with increasing age. Reduced lithium ion clearance is expected in patients with hypertension, congestive heart failure, or renal dysfunction. Larger lithium ion maintenance doses are required in obese compared with nonobese patients. The most clinically significant pharmacokinetic drug interactions associated with lithium involve drugs that are commonly used in the elderly and that can increase serum Li+ concentrations. People who are taking lithium should consult their physician before taking the following drugs: acetazolamide, antihypertensives, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, calcium channel blockers, carbamazepine, thiazide diuretics, hydroxyzine, muscle relaxants, neuroleptics, table salt, baking powder, tetracycline, TCAs, MAOIs, and caffeine. The tolerability of lithium is lower in elderly patients. Lithium toxicity can occur in the elderly at concentrations considered to be “therapeutic” in the general adult populations. Serum concentrations of lithium ion need to be markedly reduced in the elderly population—and particularly so in the very old and frail.

Lithium Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Lithium Suppliers

JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9984
Advantage
60
Secco work (Beijing) chemical technology co., LTD
Tel
0566-8928158
Fax
010-69755668
Email
343367102@QQ.COM
Country
China
ProdList
360
Advantage
54
Wuxi Zhongkun Biochemical Technology Co., Ltd.
Tel
0510-85629785 18013409632
Fax
051085625359
Email
sales@reading-chemicals.com
Country
China
ProdList
15185
Advantage
58
Shanghai Xilong Biochemical Technology Co., Ltd.
Tel
021-52907766-8042
Fax
021-52906523
Country
China
ProdList
9947
Advantage
58
Zhengzhou Acme Chemical Co., Ltd.
Tel
0371-0371-55629727 13323845623
Fax
037155629727
Email
2885676761@qq.com
Country
China
ProdList
9979
Advantage
58
Taian Jiaye Biotechnology Co.Ltd
Tel
13127280945
Email
285424065@qq.com
Country
China
ProdList
9980
Advantage
55
JinJin Le Chemical Co., Ltd
Tel
10106090
Email
jjlchem2@163.com
Country
China
ProdList
9986
Advantage
58
Wuhan Netcom Electronic Commerce Limited
Tel
18064670521
Fax
0757-88210752
Email
2355935187@ycphar.com
Country
China
ProdList
4887
Advantage
58
Aikon International Limited
Tel
025-58859352 18068836627
Fax
02557626880
Email
sales01@aikonchem.com
Country
China
ProdList
15085
Advantage
58
Hubei Zhonglong Kangsheng Fine Chemical Co., Ltd.
Tel
15926260361
Fax
QQ:1930063008
Email
1930063008@qq.com
Country
China
ProdList
5094
Advantage
58
More
Less

View Lastest Price from Lithium manufacturers

Career Henan Chemical Co
Product
LITHIUM ION CHROMATOGRAPHY STANDARD 17341-24-1
Price
US $1.00/g
Min. Order
1g
Purity
99%
Supply Ability
10000KGS
Release date
2020-01-10